Table 3.
Association between serum levels of CRP-bound SAA (CRP-SAA), total SAA and clinical characteristics of the 464 lung cancer patients
| Characteristic | CRP-SAA [cases (%)] | P value | Total SAA [cases (%)] | P value | ||
|---|---|---|---|---|---|---|
| Low level (OD ≤ 0.10) | High level (OD > 0.10) | Low level (OD ≤ 0.17) | High level (OD > 0.17) | |||
| Total | 212 | 252 | 271 | 193 | ||
| Age | 0.725 | 0.741 | ||||
| <60 years | 112 (24.1) | 129 (27.8) | 139 (30.0) | 102 (22.0) | ||
| ≥60 years | 100 (21.6) | 123 (26.5) | 132 (28.4) | 91 (19.6) | ||
| Sex | 0.001 | 0.106 | ||||
| Male | 142 (30.6) | 203 (43.8) | 194 (41.8) | 151 (32.5) | ||
| Female | 70 (15.1) | 49 (10.6) | 77 (16.6) | 42 (9.1) | ||
| Smoking status | <0.001 | <0.001 | ||||
| No | 113 (24.4) | 85 (18.3) | 139 (30.0) | 59 (12.7) | ||
| Yes | 99 (21.3) | 167 (36.0) | 132 (28.4) | 134 (28.9) | ||
| Treatment | <0.001 | <0.001 | ||||
| Multimodality therapy without operation | 86 (18.5) | 54 (11.6) | 112 (24.1) | 28 (6.0) | ||
| Operation alone | 62 (13.4) | 76 (16.4) | 82 (17.7) | 56 (12.1) | ||
| Operation and multimodality therapy | 64 (13.8) | 122 (26.3) | 77 (16.6) | 109 (23.5) | ||
| T stage | <0.001 | <0.001 | ||||
| T1 | 41 (8.8) | 29 (6.3) | 54 (11.6) | 16 (3.4) | ||
| T2 | 109 (23.5) | 100 (21.6) | 130 (28.0) | 79 (17.0) | ||
| T3 | 32 (6.9) | 82 (17.7) | 51 (11.0) | 63 (13.6) | ||
| T4 | 30 (6.5) | 41 (8.8) | 36 (7.8) | 35 (7.5) | ||
| N stage | <0.001 | <0.001 | ||||
| N0 | 93 (20.0) | 72 (15.5) | 113 (24.4) | 52 (11.2) | ||
| N1 | 33 (7.1) | 41 (8.8) | 47 (10.1) | 27 (5.8) | ||
| N2 | 68 (14.7) | 90 (19.4) | 84 (18.1) | 74 (15.9) | ||
| N3 | 18 (3.9) | 49 (10.6) | 27 (5.8) | 40 (8.6) | ||
| M stage | <0.001 | <0.001 | ||||
| M0 | 174 (37.5) | 155 (33.4) | 213 (45.9) | 116 (25.0) | ||
| M1 | 38 (8.2) | 97 (20.9) | 58 (12.5) | 77 (16.6) | ||
| Clinical stage | <0.001 | <0.001 | ||||
| I | 57 (12.3) | 19 (4.1) | 61 (13.1) | 15 (3.2) | ||
| II | 41 (8.8) | 42 (9.1) | 60 (12.9) | 23 (5.0) | ||
| III | 76 (16.4) | 94 (20.3) | 92 (19.8) | 78 (16.8) | ||
| IV | 38 (8.2) | 97 (20.9) | 58 (12.5) | 77 (16.6) | ||
| Pathologic type | 0.192 | 0.784 | ||||
| Adenocarcinoma | 112 (24.1) | 131 (28.2) | 147(31.7) | 96(20.7) | ||
| Squamous cell carcinoma | 65 (14.0) | 65 (14.0) | 72 (15.5) | 58 (12.5) | ||
| Small cell carcinoma | 15 (3.2) | 33 (7.1) | 26 (5.6) | 22 (4.7) | ||
| Others | 20 (4.3) | 23 (5.0) | 26 (5.6) | 17 (3.7) | ||
| Primary tumor site | 0.821 | 0.301 | ||||
| Left lung | 86 (18.5) | 107 (23.1) | 105 (22.6) | 88 (19.0) | ||
| Right lung | 126 (27.2) | 145 (31.3) | 166 (35.8) | 105 (22.6) | ||
The Mann-Whitney U test was used to analyze the associations. Tumor size, lymph node involvement, distant metastasis, and clinical stage were classified according to the seventh edition of the Union for International Cancer Control (UICC) Staging system for Lung Cancer.
P < 0.05 is considered significant and the P-value is in italics.
OD optical density.